Aim: A prospective, randomised study to evaluate effects of brinzolamide on ocular haemodynamics in healthy volunteers. Methods: 30 volunteers (12 men, 18 women; 28.3 (SD 7.8) years) were prospectively randomised to either brinzolamide or placebo during a 2 week double masked treatment trial. Examinations were performed at baseline and after 2 weeks of treatment. Intraocular pressure was measured and automatic static perimetry (Humphrey field analyser, 24-2) and contrast sensitivity (CSV 1000, Vector Vision) were performed. Retrobulbar blood flow velocities (peak systolic and end diastolic velocity) and resistive indices (RI) of ophthalmic artery, central retinal artery and of temporal and nasal short posterior ciliary arteries were measured by colour Doppler imaging (Sonoline Sienna Siemens). In video fluorescein angiograms (scanning laser ophthalmoscope, Rodenstock) arteriovenous passage time (AVP, dilution curves) and peripapillary diameters of retinal arterioles and venules were measured by means of digital image analysis. Results: Intraocular pressure was significantly decreased by brinzolamide (p,0.0001). Neither brinzolamide nor placebo changed visual field global indices after treatment. Contrast sensitivity at 3 cycles per degree was significantly higher in the placebo group (p,0.05). Apart from an increase of RI in ophthalmic artery under placebo treatment (p,0.05) there was no effect in retrobulbar haemodynamics in both groups. Brinzolamide therapy alone resulted in a significant reduction of AVP compared to baseline (p,0.05), while peripapillary retinal vessels diameters remained unaffected. Conclusions: Apart from the expected decrease of intraocular pressure brinzolamide showed no significant change in retrobulbar haemodynamics, but a significant shortening of AVP. Since in glaucoma AVP is prolonged indicating vascular dysfunction this effect might be beneficial in glaucoma therapy.

Central serous chorioretinopathy (CSCR) can lead to permanent visual loss in chronic cases. We report on a 57-year-old female patient with persistent findings over 6 months despite conservative therapy. A single intravitreal injection of bevacizumab led to a rapid morphologic and functional restitution without relapse or complication during the 19 weeks period after injection. Intravitreal injection of bevacizumab could be a therapeutic option for the treatment of chronic CSCR, however the results of appropriate studies must be awaited before it can be introduced into routine use.

Geschützte Warennamen (Warenzeichen) werden nicht besonders kenntlich gemacht. Aus dem Fehlen eines solchen Hinweises kann also nicht geschlossen werden, dass es sich um einen freien Warennamen handelt.

Glaukome sind weltweit eine der h?ufigsten Erblindungsursachen. Nach den Leitlinien der European Glaucoma Society (EGS) 7 werden Operationen f?r die h?ufigsten Glaukomformen erst nach Aussch?pfen der konservativen Behandlung empfohlen. In weniger entwickelten L?ndern dagegen sind sie h?ufig die erste Wahl. Nachfolgend sollen die nichtpenetrierenden Verfahren beschrieben und ihr heutiger Stellenwert diskutiert werden.

No abstract